Saccharomyces cerevisiae Fermentate
Saccharomyces cerevisiae
Also known as: Yeast fermentate, EpiCor, Baker's yeast fermentate
This ingredient is classified as unclassified risk (GIRI score: 1.5/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Saccharomyces cerevisiae fermentate (e.g., EpiCor) is a dried yeast fermentate used for immune modulation. It is well tolerated in healthy adults. People with severe yeast allergies should use with caution. No significant drug interactions documented. Immunocompromised individuals should consult a physician before use.
Biological and Chemical Classification
- Scientific Name
- Saccharomyces cerevisiae
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Immune Support
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Saccharomyces cerevisiae Fermentate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:34
Evidence Distribution
-
Observational / other LOW evidence YELLOWNative microorganisms as natural enhancers in craft beer and wine production. ↗Caiza-Valencia C et al.. Native microorganisms as natural enhancers in craft beer and wine production.. Front Microbiol. 2026. PMID:41883801.PMID 41883801 ↗Journal Front MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41883801/
-
Observational / other LOW evidence YELLOWPeptidomic profiling and molecular dynamics study of bioactive peptides from fermented camel milk: considering the fermentation time dependent proteolysis by Lactobacillus and… ↗Padhiyar PN et al.. Peptidomic profiling and molecular dynamics study of bioactive peptides from fermented camel milk: considering the fermentation time dependent proteolysis by Lactobacillus and Saccharomyces with antidiabetic, antioxidative and anti-inflammatory activities.. Front Nutr. 2026. PMID:41883408.PMID 41883408 ↗Journal Front NutrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41883408/
-
Observational / other LOW evidence YELLOWInfluence of Ploidy and Genetic Background on Stress Tolerance of Intraspecific Yeast Hybrids. ↗Rinta-Harri K et al.. Influence of Ploidy and Genetic Background on Stress Tolerance of Intraspecific Yeast Hybrids.. Microb Biotechnol. 2026. PMID:41882949.PMID 41882949 ↗Journal Microb BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41882949/
-
Observational / other LOW evidence YELLOWAntioxidant and anti-aging properties of a Zn-complex in Saccharomyces cerevisiae: A non-canonical protective mechanism. ↗Ribeiro TP et al.. Antioxidant and anti-aging properties of a Zn-complex in Saccharomyces cerevisiae: A non-canonical protective mechanism.. J Inorg Biochem. 2026. PMID:41880774.PMID 41880774 ↗Journal J Inorg BiochemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41880774/
-
Observational / other LOW evidence YELLOWDriving impact of organic acids on microbial community dynamics and fermentation performance in Huangjiu. ↗Cheng S et al.. Driving impact of organic acids on microbial community dynamics and fermentation performance in Huangjiu.. NPJ Sci Food. 2026. PMID:41876559.PMID 41876559 ↗Journal NPJ Sci FoodYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41876559/
-
Observational / other LOW evidence YELLOWSynthetic rescue in Saccharomyces cerevisiae: Concepts, large-scale genetic mapping, and functional implications. ↗Choi JE et al.. Synthetic rescue in Saccharomyces cerevisiae: Concepts, large-scale genetic mapping, and functional implications.. J Microbiol. 2026. PMID:41876442.PMID 41876442 ↗Journal J MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41876442/
-
Observational / other LOW evidence YELLOWPrediction of gene expression levels in Saccharomyces cerevisiae based on chromatin accessibility using multiple machine learning models. ↗Dong B et al.. Prediction of gene expression levels in Saccharomyces cerevisiae based on chromatin accessibility using multiple machine learning models.. Comput Biol Chem. 2026. PMID:41875746.PMID 41875746 ↗Journal Comput Biol ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41875746/
-
Observational / other LOW evidence YELLOWSaccharomyces cerevisiae as a model for mammalian diseases. ↗Sattlegger E et al.. Saccharomyces cerevisiae as a model for mammalian diseases.. FEMS Yeast Res. 2026. PMID:41874417.PMID 41874417 ↗Journal FEMS Yeast ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41874417/
-
Observational / other LOW evidence YELLOWElucidation and Reconstitution of the Andrographolide Biosynthetic Pathway in Saccharomyces cerevisiae. ↗Li S et al.. Elucidation and Reconstitution of the Andrographolide Biosynthetic Pathway in Saccharomyces cerevisiae.. ACS Synth Biol. 2026. PMID:41874273.PMID 41874273 ↗Journal ACS Synth BiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41874273/
-
Observational / other LOW evidence YELLOWAn MNase-ChIP-Seq Protocol to Profile Histone Modifications at a DNA Break in Yeast. ↗Di Nisio E et al.. An MNase-ChIP-Seq Protocol to Profile Histone Modifications at a DNA Break in Yeast.. Methods Protoc. 2026. PMID:41874159.PMID 41874159 ↗Journal Methods ProtocYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41874159/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Saccharomyces cerevisiae Fermentate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Saccharomyces cerevisiae Fermentate
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.